curve lines

NEPTIS® Perform Duo

Two Modes. One Module.

  • [18F]FDG
  • [18F]NaF
  • [18F]FLT
  • [18F]FMISO
  • [18F]FHBG
  • [18F]FCH
  • [18F]FET
  • [18F]FES
  • [18F]PSMA1007
  • [18F]F-L-DOPA
  • [68Ga]Ga-tracers
  • [177Lu]Lu-tracers
  • Built on the proven NEPTIS® Perform (platform)

    Produce the widest range of [18F] fluoride-based radiotracers where complex chemistry becomes routine and reliable production.

  • R&D and routine onto one module

    Develop tracer sequences without kits and produce them routinely on one module, with the same chemistries, cassettes and yields.

  • NEPTIS Perform Duo
  • NEPTIS Perform Duo
  • NEPTIS Perform Duo
  • NEPTIS Perform Duo
  • image
  • NEPTIS Perform Duo
  • NEPTIS Perform Duo
  • Actuators

    4 ramps of 5 three-position pneumatic actuators

  • HPLC (option)

    HPLC drawer and pathways, 1 injection valve, 1 rad detector (sensitivity < 2mCi) (WNE® technology)

  • Detectors

    5 rad detectors (+1 optional), 1 UV signal

  • Hot cell compatibility

    Fits standard shielded hot cells

  • Syringe drivers

    3 (30 mL and 10/3 mL)

  • Dimensions

    560 x 420 x 400 mm | 22.0 x 16.5 x 15.7 in (w x h x d)

  • Heating & Reactor ovens

    1 (+1 optional)

  • Weight

    38 kg / 84 lbs

  • Sensors

    Vacuum, flow and pressure

  • Ready-to-use cassettes available

    Yes

  • UV detection

    MWD UV detector via optical fibers (electronics protected)

  • Software

    Browser‑based NEPTIS® Control with Designer and Trending for method development and run analytics

  • Two in One

    Single-use cassettes for routine GMP production, reusable PEEK manifolds for development, with conversion in either direction. NEPTIS® Perform Duo is the only synthesizer that switches consumable mode on the same hardware and software.

  • Reusable manifold

    With reusable PEEK manifolds, each iteration costs only operator time and reagents. Over 30 reuses demonstrated in internal testing, using the NEPTIS® xSeed™ cleaning procedure.

  • Reliable

    Built with proven NEPTIS® Perform platform, with the same cassettes, chemistry, yields and workflow, so your team is productive on day one. Sequences developed move straight into routine production on the same module, with one qualification and one set of paperwork.

  • Scalable

    Start with a base configuration and grow with your pipeline. Add HPLC column selection, a quaternary pump, extra detectors or a second reactor oven, including FDG dual-run options as you need them.

curve lines
  • Interested to learn more about NEPTIS® Perform Duo?

    Download product information

    Find out everything you need to know about NEPTIS® Perform Duo.

  • iba press release
    • 19/10/2026
    IBA launches NEPTIS® Perform Duo, one synthesizer module from tracer development to routine production

    Louvain-la-Neuve, Belgium, October 19th, 7 a.m. - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the leading provider of radiopharmaceutical production solutions, today announces it has unveiled NEPTIS® Perform Duo, a synthesizer that lets radiopharmaceutical producers develop new tracers and manufacture them on one module, on October 18 at the EANM'26 Congress in Vienna, Austria.

     

    A radiopharmaceutical synthesizer is an automated system that combines a radioisotope with specific chemical compounds to produce a radiopharmaceutical for diagnostic imaging or therapeutic use. It plays a crucial role in radiopharmaceutical production by automating and precisely controlling the chemical processes required to transform a radioisotope into a safe, consistent and ready-to-use drug.

     

    Developing a new PET imaging agent, known as a tracer, takes many trial runs. On most synthesizers, each run uses a new single-use kit. As a result, producers that both develop and manufacture tracers often rely on two separate systems.

     

    NEPTIS® Perform Duo brings both steps onto one module. For development, it uses reusable components, reused more than 30 times in internal testing, which lowers consumable costs. For production, it runs the same single-use cassettes and chemistries as NEPTIS® Perform, including FDG, the most widely used PET tracer. Because the system stays the same, the process a team develops is the process it produces, with one qualification path.

     

    It is the first new product from ORA, since IBA acquired ORA in December 2025. The launch reflects IBA's commitment to radiochemistry as it builds a fully integrated offering for radiopharmaceutical manufacturers. Designed for contract manufacturers, commercial radiopharmaceutical producers and radiopharmacy networks, the new module joins NEPTIS® Perform and NEPTIS® xSeed™ in the NEPTIS® range.

     

    “Our customers increasingly develop the tracers they later manufacture, and they want to do both on the same platform,” said Loïk-Maël Nys, President of IBA RadioPharma Solutions.“NEPTIS® Perform Duo gives them a simpler and more economical way to take a new compound from first run to routine production. For the teams we work with, that helps bring new diagnostic options to patients sooner.”

     

    ORA brings 20 years of radiochemistry expertise, with NEPTIS® synthesizers installed at more than 600 sites in over 50 countries. Combined with IBA's four decades of experience in cyclotrons, the machines that produce medical isotopes, this gives radiopharmaceutical producers one partner from isotope production to dose-ready radiopharmaceutical.

    More details
  • NEPTIS Perform Duo
    • 19/10/2026
    IBA launches NEPTIS® Perform Duo

    Two modes in one module. Sequences developed on NEPTIS® Perform Duo move straight into routine production on the same module, with one qualification and one set of paperwork.

    More details
  • Brochure NEPTIS Perform
    • 19/10/2026
    Brochure NEPTIS® Perform Duo

    NEPTIS® Perform Duo is a cassette-based synthesizer built on NEPTIS® Perform platform that also runs reusable manifolds.

    More details
curve lines
Thought Leadership

Building the future of Astatine-211, the POLATOM perspective

  • 07/07/2026

Prof Dr Renata Mikolajczak, PhD - Research and Cooperation Manager, Radioisotope Center POLATOM National Center for Nuclear Research, Poland.

With over 30 years in radioisotope and radiopharmaceutical development, Prof Dr Renata Mikolajczak is coordinating the research activity of the Radioisotope Centre POLATOM, National Centre for Nuclear Research in Poland.

She is a Professor of medical sciences and holds a Ph.D. in physics and a DSc in medical biology.

Since 2020, she has served as the chair of the expert group, PRP Working Party - Precursors for Radiopharmaceutical Preparations,  European Pharmacopoeia of EDQM

She is a IAEA expert and lecturer in Radiopharmacy and member of the IAEA’s Standing Advisory Group on Nuclear Applications (SAGNA).

curve lines
Thought Leadership

Whitepaper | Securing the Radiopharmaceutical Supply Chain

  • 25/06/2026
White paper Securing the Radiopharmaceutical Supply Chain

Securing the Radiopharmaceutical Supply Chain: From Structural Fragility to Strategic Alliance

Everyone in the industry has seen the $12–14 billion projection for 2030. This white paper addresses the main question: what would actually have to change across the full chain for that number to become real? 
 

Jean-Michel Geets, Principal Domain Expert & IBA Fellow
Louise Piron, Marketing Manager

Discover the 10 structural fault lines across supply and demand

curve lines
Publication

211At targeted alpha therapy in Europe: overcoming clinical, regulatory, and infrastructure challenges

  • 29/05/2026
Publication

Abstract

Hugo Levillain, Anne Royer Moës, Cristiana Gameiro-Paris, Antero Abrunhosa, Tom Deakin, Geraldine Gebhart, Matthias M. Herth, Jean-François Gestin, Ferid Haddad, Andreas Ingemann Jensen, Rebecca Lo Bue, Renata Mikolajczak, Adrian Otamendi, Katie Staunton-Mann, Kevin Tabury & Patrick Flamen on behalf of the Accelerate.EU consortium

 

Targeted Alpha Therapy (TAT) holds considerable promise for precision oncology, yet its clinical deployment in Europe remains limited. Beyond scientific considerations, progress is constrained by fragmentation across the radiopharmaceutical value chain, encompassing radionuclide production, radiochemistry, preclinical validation, clinical development, regulatory frameworks, infrastructure, and workforce training. 

Read the full PDF version of this publication

Publication available in open access

curve lines
Thought Leadership

Alpha emitters and the future of radiopharmaceutical therapy

  • 28/04/2026

Prof Dr Ekaterina Dadachova

Ekaterina (Kate) Dadachova, PhD, joined University of Saskatchewan in Canada late in 2016 as a Fedoruk Center for Nuclear Innovation Chair in Radiopharmacy, and a Professor of Pharmacy.
 

Before joining University of Saskatchewan, she held a Professorship in Radiology, Microbiology and Immunology at the Albert Einstein College of Medicine in New York, USA from 2000 to 2016.

Her research interests are radioligand therapy of cancer, infections and autoimmune diseases, as well as interaction of melanized fungi with ionizing radiation and melanin-based radioprotectors.
 

She published more than 210 papers, 13 book chapters, and has 8 US patents. She received several awards such as Philips Young Investigator Award by RSNA, Young Professionals Award from the SNM, Mary Kay Ash Research Award, Top 10 researchers at the Albert Einstein College of Medicine in 2013, 2017 Burroughs Welcome Award, 2020 University of Saskatchewan Distinguished Researcher Award and 2024 Saskatchewan Health Research Foundation (SHRF) Years of Service Award. She is in the top 2% of cited scientists worldwide according to Stanford University 2024 database.
 

Prof Dr Ekaterina Dadachova, PhD

  • Professor, College of Pharmacy and Nutrition
    & Editor in Chief, Cancer Biotherapy and Radiopharmaceuticals
  • Sylvia Fedoruk Center for Nuclear Innovation Chair in Radiopharmacy University of Saskatchewan, Canada
curve lines
Thought Leadership

Challenges & Opportunities in Nuclear Medicine

  • 15/09/2025

Prof Dr Rudi Dierckx

  • Past President of European Association of Nuclear Medicine (2023 - 2024)


Prof Dr Rudi Dierckx highlights the key industry challenges and opportunities in nuclear medicine.

Discover the next episode of our Expert Spotlight Series

Prof Dr Parthiban Arumugam | The Rising clinical value of quantitative cardiac perfusion PET.

curve lines
Thought Leadership

Latest Research in Nuclear Medicine

  • 08/09/2025

Prof Dr Rudi Dierckx

  • Past President of European Association of Nuclear Medicine (2023 - 2024)


Prof Dr Dierckx explores the research that is opening new perspectives across all therapeutic areas.

Discover the next episode of our Expert Spotlight Series

Prof Dr Rudi Dierckx | Challenges & Opportunities

curve lines
Thought Leadership

Main trends in Nuclear Medicine

  • 01/09/2025

Prof Dr Rudi Dierckx

  • Past President of European Association of Nuclear Medicine (2023 - 2024)

 

Prof Dr Rudi Dierckx navigates through the evolving landscape of nuclear medicine, from the significant advancements to the growing interest of pharmaceutical industry.

Discover the next episode of our Expert Spotlight Series

Prof Dr Rudi Dierckx | Latest Research

curve lines
Publication

Detailed study of the distribution of activation inside the magnet coils of a compact PET cyclotron

  • 14/10/2021
Publication

Abstract

V. Bonvina ,b, *, F. Bochudb, J. Damet b,d , C. Theisa, H. Vinckea,c, R. Geyera,b
aEuropean Council for Nuclear Research (CERN), Esplanade des Particules, CH-1211, Meyrin, Switzerland
bInstitute for Radiation Physics, Lausanne University Hospital, Rue du Grand-Pr´ e, CH-1007, Lausanne, Switzerland
cUniversity of Technology, Rechbauerstraße 12, 8010, Graz, Austria
dUniversity of Otago, 2 Riccarton Ave, Christchurch, New Zealand   

curve lines

Read the full PDF version of this publication

curve lines
Publication

Securing Gallium-68 availability with liquid target production on mid-energy cyclotrons: Users' experience

  • 14/10/2021
Poster

Poster

C. Gameiro1, V. H. Alves2, A. Abrunhosa3, F. Alves2, D. Goblet1, B. Nactergal1, A. Uhlending3, V. Hugenberg3, T. Ortgies3, G. Hoeger3, J. Manrique-Arias4, R. Freifelder5, K. Hye-Yeong5, M. Bhuiyan5,  A. Kucharski5 
1IBA, Louvain-La-Neuve, BELGIUM,
2Institute for Nuclear Sciences Applied in Health (ICNAS), Coimbra, PORTUGAL,
3Department of Radiology, Nuclear medicine and Molecular Imaging, Bad Oeynhausen, GERMANY,
4Cyclotron Department, Doctors Hospital, Monterrey, MEXICO,
5Department of Radiology, University of Chicago, Chicago, IL, US.

curve lines

Read the full PDF version of this publication

Subscribe to